SK64993A3 - Hydroxamic acid derivatives, method of their preparation and medicaments with their content - Google Patents

Hydroxamic acid derivatives, method of their preparation and medicaments with their content Download PDF

Info

Publication number
SK64993A3
SK64993A3 SK649-93A SK64993A SK64993A3 SK 64993 A3 SK64993 A3 SK 64993A3 SK 64993 A SK64993 A SK 64993A SK 64993 A3 SK64993 A3 SK 64993A3
Authority
SK
Slovakia
Prior art keywords
hydroxyamino
alkyl
group
leucine
heptylsuccinyl
Prior art date
Application number
SK649-93A
Other languages
English (en)
Slovak (sk)
Inventor
Michael J Broadhurst
Paul A Brown
William H Johnson
Geoffrey Lawton
Original Assignee
Hoffmann La Roche A F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929213473A external-priority patent/GB9213473D0/en
Application filed by Hoffmann La Roche A F filed Critical Hoffmann La Roche A F
Publication of SK64993A3 publication Critical patent/SK64993A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
SK649-93A 1992-06-25 1993-06-22 Hydroxamic acid derivatives, method of their preparation and medicaments with their content SK64993A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929213473A GB9213473D0 (en) 1992-06-25 1992-06-25 Hydroxamic acid derivatives
GB939307081A GB9307081D0 (en) 1992-06-25 1993-04-05 Hydroxamic acid derivatives

Publications (1)

Publication Number Publication Date
SK64993A3 true SK64993A3 (en) 1994-01-12

Family

ID=26301123

Family Applications (1)

Application Number Title Priority Date Filing Date
SK649-93A SK64993A3 (en) 1992-06-25 1993-06-22 Hydroxamic acid derivatives, method of their preparation and medicaments with their content

Country Status (19)

Country Link
EP (1) EP0575844B1 (fi)
JP (1) JP2594014B2 (fi)
CN (1) CN1054599C (fi)
AT (1) ATE162514T1 (fi)
AU (1) AU666727B2 (fi)
BG (1) BG97895A (fi)
CA (1) CA2098166A1 (fi)
CZ (1) CZ118393A3 (fi)
DE (1) DE69316456T2 (fi)
DK (1) DK0575844T3 (fi)
ES (1) ES2112929T3 (fi)
FI (1) FI932950A (fi)
GR (1) GR3026623T3 (fi)
HU (1) HU9301773D0 (fi)
IL (1) IL106059A0 (fi)
IS (1) IS4041A (fi)
NO (1) NO932326L (fi)
NZ (1) NZ247926A (fi)
SK (1) SK64993A3 (fi)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
GB9401129D0 (en) * 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
HUT74511A (en) * 1994-01-22 1997-01-28 British Biotech Pharm Metalloproteinase inhibitors, pharmaceutical compns. contg. them and process to prepare the said compds.
GB2315750B (en) * 1994-01-22 1998-07-01 British Biotech Pharm Metalloproteinase inhibitors
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
GB9501737D0 (en) * 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
DE69510198T2 (de) * 1994-05-28 1999-10-28 British Biotech Pharmaceuticals Ltd., Cowley Succinyl hydroxamsäure-, n-formyl-n-hydroxy-aminocarbonsäure- und succinsäureamid-derivate und ihre verwendung als metalloprotease-inhibitoren
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
GB9411598D0 (en) * 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
US5840698A (en) * 1994-10-27 1998-11-24 Affymax Technologies N.V. Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
US5831004A (en) * 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5639746A (en) * 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5691381A (en) * 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
US5703092A (en) * 1995-04-18 1997-12-30 The Dupont Merck Pharmaceutical Company Hydroxamic acid compounds as metalloprotease and TNF inhibitors
GB9507799D0 (en) * 1995-04-18 1995-05-31 British Biotech Pharm Metalloproteinase inhibitors
DE69632821T2 (de) 1995-04-25 2005-08-25 Daiichi Fine Chemical Co., Ltd., Takaoka In wasser hochlöslicher metalloproteinase-inhibitor
WO1996033733A1 (fr) * 1995-04-25 1996-10-31 Fuji Yakuhin Kogyo Kabushiki Kaisha Nouveau remede pour affections cutanees
EP0824543A1 (en) * 1995-05-10 1998-02-25 Chiroscience Limited Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use
US5677282A (en) * 1995-06-07 1997-10-14 Proscript, Inc. Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
EP0873304B1 (en) 1995-11-23 2001-09-05 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
DE69716934T2 (de) * 1996-08-28 2003-07-31 The Procter & Gamble Company, Cincinnati 1,3-diheterozyklische metalloprotease inhibitoren
BR9712085A (pt) 1996-08-28 2000-10-24 Procter & Gamble Inibidores de metaloprotease heterocìclicos
AU731319B2 (en) * 1996-08-28 2001-03-29 Procter & Gamble Company, The Heterocyclic metalloprotease inhibitors
TR199900429T2 (xx) * 1996-08-28 1999-05-21 The Procter & Gamble Company Spirosiklik metaloproteaz inhibit�rleri.
PL331854A1 (en) * 1996-08-28 1999-08-16 Procter & Gamble Phosphinamides as inhibitors of metaloprotease matrix
CZ298048B6 (cs) 1996-09-10 2007-06-06 British Biotech Pharmaceuticals Limited Farmaceutický prostredek a deriváty kyseliny hydroxamové
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
ZA9818B (en) * 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
WO1999006340A2 (en) 1997-07-31 1999-02-11 The Procter & Gamble Company Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
HUP0202199A2 (en) 1999-03-03 2002-10-28 Procter & Gamble Alkenyl- and alkynyl-containing metalloprotease inhibitors
JP2001055327A (ja) * 1999-06-11 2001-02-27 Fuji Chemical Industries Ltd 新規なヒドロキサム酸誘導体を含む医薬
US6696456B1 (en) 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
IL151125A0 (en) 2000-03-21 2003-04-10 Procter & Gamble Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
CA2401728A1 (en) 2000-03-21 2001-09-27 The Procter & Gamble Company Difluorobutyric acid metalloprotease inhibitors
GB0421308D0 (en) * 2004-09-24 2004-10-27 Amersham Plc Enzyme inhibitor imaging agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
GB8601368D0 (en) * 1986-01-21 1986-02-26 Ici America Inc Hydroxamic acids
US4771038A (en) * 1986-01-21 1988-09-13 Ici Americas Inc. Hydroxamic acids
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
GB8630721D0 (en) * 1986-12-23 1987-02-04 Unilever Plc Cosmetic compositions
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
CA2073510A1 (en) * 1990-12-03 1992-06-04 Celltech Therapeutics Limited Peptidyl derivatives

Also Published As

Publication number Publication date
DE69316456D1 (de) 1998-02-26
DE69316456T2 (de) 1998-07-09
EP0575844B1 (en) 1998-01-21
EP0575844A3 (fi) 1994-03-09
ES2112929T3 (es) 1998-04-16
JPH0687813A (ja) 1994-03-29
CA2098166A1 (en) 1993-12-26
NO932326L (no) 1993-12-27
NZ247926A (en) 1995-10-26
DK0575844T3 (da) 1998-09-14
HU9301773D0 (en) 1993-09-28
GR3026623T3 (en) 1998-07-31
AU3993193A (en) 1994-01-06
IL106059A0 (en) 1993-10-20
EP0575844A2 (en) 1993-12-29
CN1082027A (zh) 1994-02-16
NO932326D0 (no) 1993-06-24
JP2594014B2 (ja) 1997-03-26
CN1054599C (zh) 2000-07-19
CZ118393A3 (en) 1994-02-16
FI932950A (fi) 1993-12-26
AU666727B2 (en) 1996-02-22
BG97895A (en) 1994-06-30
IS4041A (is) 1993-12-26
ATE162514T1 (de) 1998-02-15
FI932950A0 (fi) 1993-06-24

Similar Documents

Publication Publication Date Title
SK64993A3 (en) Hydroxamic acid derivatives, method of their preparation and medicaments with their content
US4996358A (en) Hydroxylamine bearing amino acid derivatives as collagenase inhibitors
Nishizawa et al. Synthesis and structure-activity relations of bestatin analogs, inhibitors of aminopeptidase B
US4885283A (en) Phosphinic acid derivatives
US5571792A (en) Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
US5672598A (en) Lactam-containing hydroxamic acids
EP0260118B1 (en) Selective amidination of diamines
GB2095682A (en) Compounds of the formula
PT86024B (pt) Processo para a preparacao de polipeptidos de nor-estatina e nor-cicloestatina
KR19980086847A (ko) 설포닐아미노카복실산
IE52663B1 (en) Substituted acyl derivatives of octahydro-1h-indole-2-carboxylic acids
CS621585A2 (en) Method of analynprolinone derivatives production
IE51918B1 (en) Bicyclic compounds their production and use
CZ293868B6 (cs) Přemostěné indoly jako inhibitory matricové metaloproteázy
US4500467A (en) Benzoylthio compounds, their preparation and their use as drugs
HU204539B (en) Process for producing oligopeptides containing cyclic proline-analogue amino-acids and pharmaceutical compositions contaiing them as active components
CS201033B2 (en) Method of producing derivatives of n-/3-amino-2-hydroxy-propionyl/-2-amino acetic acid
KR940006770B1 (ko) 머캅토-아실아미노산 고혈압 치료제
EP0333000B1 (en) Peptides with inhibitory activity of enzymatic systems, process for their preparation and pharmaceutical compositions containing them
US4490386A (en) Phosphate salts of 1-[2-[(1-alkoxycarbonyl-3-aralkyl)-amino]-1-oxoalkyl]octahydro-1H-indole-2-carboxylic acids, preparation of, and medical compositions thereof
PL167915B1 (pl) Sposób otrzymywania nowych N-( a-podstawionych-pirydynylo)karbonylo-dipeptydów PL PL PL
JPH0379339B2 (fi)
KR890002173B1 (ko) 치환된 디펩티드 및 이의 제조방법
US4350628A (en) Preparation of dehydropeptides
EP1864994A1 (en) Par-2 agonist